Company Filing History:
Years Active: 2018-2021
Title: Clare Balendran: Innovator in Cardiovascular Treatment
Introduction
Clare Balendran is a prominent inventor based in Molndal, Sweden. She has made significant contributions to the field of cardiovascular medicine through her innovative research and development of specific antibodies.
Latest Patents
Clare holds 2 patents related to antibodies specific for LOX1 and their use in the treatment of cardiovascular disorders. These patents disclose LOX1 binding proteins, such as anti-LOX1 antibodies, and outline compositions and methods for creating these binding proteins. The LOX1-binding proteins provided in her patents inhibit or antagonize LOX1 activity. Furthermore, the disclosures include methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia, myocardial infarction, acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, chronic inflammation, angiogenesis, preeclampsia, cancer, and other LOX1-mediated diseases and conditions.
Career Highlights
Clare is currently associated with Medimmune Limited, where she continues to advance her research in the field of cardiovascular health. Her work has been instrumental in developing therapeutic strategies that target critical cardiovascular conditions.
Collaborations
Clare has collaborated with notable colleagues, including Andrew Grier Buchanan and Matthieu Chodorge, to further enhance her research efforts and contribute to the scientific community.
Conclusion
Clare Balendran's innovative work in developing LOX1-specific antibodies represents a significant advancement in the treatment of cardiovascular disorders. Her contributions are paving the way for new therapeutic approaches that could improve patient outcomes in this critical area of medicine.